Walvax Biotechnology Co., Ltd. Class A

Walvax Biotechnology Co., Ltd. Class A

SSZSE:300142
10.38
CNY
-0.13
(-1.24%)
0.01EPS
1,042.28P/E
22.76BMarket Cap
Mar 29Next Earn

Total Valuation

CNY

As of September 30, 2026, Walvax Biotechnology Co., Ltd. Class A carries a market capitalization of 22.76B, placing it among publicly traded companies globally. Its enterprise value stands at 23.61B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap22.76B
Enterprise Value23.61B

Important Dates

Walvax Biotechnology Co., Ltd. Class A's next confirmed earnings release is scheduled for March 29, 2027.

Earnings Date3/29/2027

Share Statistics

As of September 30, 2026, Walvax Biotechnology Co., Ltd. Class A has 1.60B shares outstanding.

Shares Outstanding1.60B

Valuation Ratios

As of September 30, 2026, Walvax Biotechnology Co., Ltd. Class A trades at a trailing price-to-earnings ratio of 1,042.28. The price-to-sales ratio is 12.33, and the price-to-book ratio stands at 3.28.

PE Ratio1,042.28
PS Ratio12.33
PB Ratio3.28
P/TBV Ratio4.15

Enterprise Valuation

As of September 30, 2026, Walvax Biotechnology Co., Ltd. Class A trades at an EV/EBITDA multiple of 304.89 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 12.79 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 304.89 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 23.61B versus a market cap of 22.76B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales12.79
EV / EBITDA304.89
EV / EBIT304.89

Financial Position

As of September 30, 2026, Walvax Biotechnology Co., Ltd. Class A maintains a current ratio of 2.01, meaning it holds 2.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 19.27, indicating elevated leverage, while an interest coverage ratio of 2.73 demonstrates limited ability to service its debt obligations.

Current Ratio2.01
Quick Ratio0.46
Debt / Equity19.27
Debt / EBITDA18.14
Interest Coverage2.73

Financial Efficiency

CNY

These figures cover the twelve months ended September 30, 2026. The company generates approximately 932,026.33 in revenue per employee across its workforce of 1,981.00, a quick read on workforce productivity versus industry peers.

Revenue Per Employee932,026.33
Employee Count1,981.00

Taxes

CNY

Over the twelve months ended September 30, 2026, Walvax Biotechnology Co., Ltd. Class A recorded 35.15M in income tax expense. That works out to an effective tax rate of 65.63, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 53.57M, leaving 21.84M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax35.15M
Effective Tax Rate65.63

Stock Price Statistics

CNY

As of the close on November 17, 2026, Walvax Biotechnology Co., Ltd. Class A's stock has declined approximately 17.55% over the past 52 weeks. The 50-day moving average sits at 12.69, while the 200-day moving average is 12.76.

52-Week Price Change-17.55%
50-Day Moving Average12.69
200-Day Moving Average12.76

Income Statement

CNY

Over the twelve months ended September 30, 2026, Walvax Biotechnology Co., Ltd. Class A generated 1.85B in revenue and converted that into 21.84M in net income, yielding earnings per share of 0.01. EBITDA reached 77.43M, while operating income came in at 207.25M.

Revenue1.85B
Gross Profit1.34B
Operating Income207.25M
Pretax Income53.57M
Net Income21.84M
EBITDA77.43M
EBIT77.43M
Earnings Per Share (EPS)0.01

Balance Sheet

CNY

As of September 30, 2026, Walvax Biotechnology Co., Ltd. Class A holds 906.87M in cash and equivalents against 1.40B in total debt, resulting in a net debt position of 382.04M. Total book value stands at 6.93B, with working capital of 1.98B providing operational flexibility.

Cash & Cash Equivalents906.87M
Total Debt1.40B
Net Debt382.04M
Equity (Book Value)6.93B
Book Value Per Share4.34
Working Capital1.98B

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-376.17M

Margins

Over the twelve months ended September 30, 2026, Walvax Biotechnology Co., Ltd. Class A posted a gross margin of 72.34, reflecting its pricing power and cost economics. The operating margin of 11.22 and net profit margin of 1.18 provide insight into operational efficiency.

Gross Margin72.34
Operating Margin11.22
Pretax Margin2.90
Profit Margin1.18
EBITDA Margin4.19

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Walvax Biotechnology Co., Ltd. Class A paid dividends of 0.17 per share. The dividend payout ratio of 1,830.09 exceeds 100%, meaning the company is distributing more than it earns and funding the dividend from cash reserves, asset sales, or borrowing, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 5.40, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Walvax Biotechnology Co., Ltd. Class A shareholders.

Dividend Per Share0.17
Payout Ratio1,830.09
Shareholder Yield5.40

Stock Splits

Walvax Biotechnology Co., Ltd. Class A's most recent stock split took place on November 10, 2015 with a 1:3 split ratio.

Last Split Date11/10/2015
Split Ratio1:3

Scores

As of September 30, 2026, Walvax Biotechnology Co., Ltd. Class A has an Altman Z-Score of 5.34, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score5.34